Molecular genetics of the debrisoquin-sparteine polymorphism.
about
Role of cytochrome P450 in drug interactionsBiotransformation and pharmacokinetics of ethylmorphine after a single oral dose.Ecstasy: are animal data consistent between species and can they translate to humans?Polymorphism in the metabolism of drugs, including antidepressant drugs: comments on phenotypingAn investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systemsInhibition of human cytochrome P450 2D6 (CYP2D6) by methadone.Molecular heterogeneity of the XbaI defined 44kb allele of the CYP2D locus within the Caucasian population.The pharmacogenomics of HIV therapy.The debrisoquine metabolic phenotype and DNA-based assays: implications of misclassification for the association of lung cancer and the debrisoquine metabolic phenotypeHuman cytochromes P450: evolution and cDNA-directed expression.Relationship between Type A and B personality and debrisoquine hydroxylation capacityThe hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotypeNo association between CYP2D6 polymorphisms and personality trait in JapaneseA novel cis-acting element controlling the rat CYP2D5 gene and requiring cooperativity between C/EBP beta and an Sp1 factor.Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study.AVP-786 for the treatment of agitation in dementia of the Alzheimer's type.Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics.Possible role of cytochromes P450 in lupus erythematosus and related disorders.The application of in vitro models of drug metabolism and toxicity in drug discovery and drug development.Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins.New opportunities in cancer risk evaluation using PCR-based DNA analysis for CYP2D6.Role of human cytochrome P-450s in risk assessment and susceptibility to environmentally based disease.In vitro methods for assessing human hepatic drug metabolism: their use in drug development.Genetic polymorphisms in human drug-metabolizing enzymes: potential uses of reverse genetics to identify genes of toxicological relevance.Synthetic strategies to lower affinity for CYP2D6.[Pharmacogenetics: what about Morocco?]Influence of amino acid residue 374 of cytochrome P-450 2D6 (CYP2D6) on the regio- and enantio-selective metabolism of metoprolol.A validated SIM GC/MS method for the simultaneous determination of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan and 3-hydroxymorphinan in biological matrices and its application to in vitro CYP2D6 and CYP3A4 inhibition study.Sparteine metabolism in a Nigerian population.CYP2D6 genotype and phenotype in Amerindians of Tepehuano origin and Mestizos of Durango, Mexico.
P2860
Q21245066-4FA1FBCF-C44E-4113-BAA6-0E31920AC7D6Q28367979-C83B8F55-E95F-4315-A7C6-97FEAD1E2A73Q31033315-99E52F79-1B62-4C2A-B9F2-4E014B3CD465Q33921325-C2C62DA4-AC43-49A8-AE57-5082A30629E2Q34347566-4388715E-2F06-41A1-90FA-C9132997CB51Q34403471-19C987A6-E6B5-4899-9736-F41D14DBDA58Q34403562-84CE2CF7-2C31-4BF4-9CA2-3A3DDE85A5EAQ34574033-EA074FA0-9530-424B-BF51-D0C936BF8B9CQ34843826-E59A9005-8800-4868-A11C-064A00DD989DQ34844146-6CFA3D87-9D25-4D5F-A606-7D6BAC31051FQ35826154-D48C8DE0-6D97-4FE0-95A2-A0360FCF07E3Q35872606-EB390B90-7807-4053-9A6E-CC033B8D6642Q36024499-6362CC1D-5399-4DF7-9EEA-DDCE494246C0Q36646897-5E5FF2CC-36CD-470F-AF3A-A8695FDF85FFQ38840508-F98C005C-1C95-4325-852D-87116572FA60Q39034436-DA354B91-2F02-4F9E-8995-3A5C29AFB9D6Q39334142-63BE5826-D9C0-4561-BA7B-5F6D4C4B3BC9Q40498843-AE8E21B4-AD2C-457C-8CE7-4A99AE8F44BBQ40537932-D9D99193-06BE-499E-B690-FE6E7AFD13CAQ40700838-0BE6B0DD-7C4E-4212-BE9B-AFDC074F051FQ40733456-DB7AC317-6C3C-4636-8924-83B34DCAAB29Q40775732-E5B443CB-2FDF-49CF-BF6C-4EEBD6F17798Q40817420-3508BB00-07E6-403C-8FEE-EE01E112F3B1Q40902474-0124580B-0E50-4BC0-8D27-2A71539ED402Q41057041-4D1C6675-2B38-40C6-AD9B-401E5E9ED30CQ42038194-51A6E898-25AC-4047-A8FC-F3AF49739A7FQ42982527-D84052E3-9AFB-492E-BEED-276CDD42BDCBQ46010800-A61A617E-5B6C-49DD-A696-38FF3CD9D9C4Q46855296-A9149A47-2B37-451C-BDA8-A1998476FC98Q54605695-27F57E02-1D58-42B9-A2F7-9628D2C0F79F
P2860
Molecular genetics of the debrisoquin-sparteine polymorphism.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Molecular genetics of the debrisoquin-sparteine polymorphism.
@ast
Molecular genetics of the debrisoquin-sparteine polymorphism.
@en
type
label
Molecular genetics of the debrisoquin-sparteine polymorphism.
@ast
Molecular genetics of the debrisoquin-sparteine polymorphism.
@en
prefLabel
Molecular genetics of the debrisoquin-sparteine polymorphism.
@ast
Molecular genetics of the debrisoquin-sparteine polymorphism.
@en
P356
P1476
Molecular genetics of the debrisoquin-sparteine polymorphism.
@en
P2093
P304
P356
10.1038/CLPT.1991.131
P407
P577
1991-09-01T00:00:00Z